Oncimmune (LON:ONC) posted its earnings results on Tuesday. The company reported GBX (5.70) (($0.08)) earnings per share for the quarter, Bloomberg Earnings reports. Oncimmune had a negative net margin of 2,521.78% and a negative return on equity of 81.75%. The business had revenue of GBX 800 million during the quarter.
Oncimmune (LON:ONC) opened at GBX 145.50 ($2.01) on Thursday. Oncimmune has a fifty-two week low of GBX 100 ($1.38) and a fifty-two week high of GBX 150 ($2.07). The firm has a market cap of $88.48 and a price-to-earnings ratio of -1,455.00.
A number of research analysts recently weighed in on ONC shares. Berenberg Bank started coverage on shares of Oncimmune in a report on Friday, January 19th. They issued a “buy” rating and a GBX 169 ($2.33) target price for the company. Bryan, Garnier & Co raised their target price on shares of Oncimmune from GBX 154 ($2.13) to GBX 168 ($2.32) and gave the company a “buy” rating in a report on Tuesday.
Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.
Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.